CAS: 379231-04-6; N-(5-Chlorobenzo[d][1,3]Dioxol-4-yl)-7-(2-(4-Methylpiperazin-1-yl)Ethoxy)-5-((Tetrahydro-2H-Pyran-4-yl)Oxy)Quinazolin-4-Amine

该化合物是一个小分子抑制剂,主要以其作为Src 家族有选择性抑制剂的作用而闻名,其特点是能够干扰各种癌症中经常受控制体弱的细胞信号路径,使其成为癌症研究和治疗的一个对象.Saracatinib有一个分子公式,反映其复杂结构,包括有助于其生物活动的多种功能组.该化合物通常通过口服方式施用,并在临床试验中调查其在处理固体肿瘤和血癌方面的效力.其药用植物动力特性包括中度吸收和新陈代谢,重点是其安全特征和潜在副作用.作为一种有针对性的疗法,Saracatinib展示了肿瘤方面个人化医学的趋势,目的是通过具体抑制肿瘤生长和生存的关键途径来改善治疗结果.

结构式图片

合成工艺路线路线简述

    海关参考信息

    专利信息


    专利号:US-2024400576-A1
    优先权日:2021-09-03
    标 题:Nitrogen-containing derivatives of salinomycin, synthesis and uses thereof
    发明人:RODRIGUEZ RAPHAËL; CZERWONKA DOMINIKA; ANTOSZCZAK MICHAL; HUCZYNSKI ADAM
    权利人:CENTRE NAT RECH SCIENT; INST CURIE; INST NAT SANTE RECH MED; ADAM MICKIEWICZ UNIV
    摘要:The present invention relates to nitrogen-containing derivatives of salinomycin having the formula (I), as well as pharmaceutically acceptable salt thereof, and synthesis and uses thereof, in particular for the treatment and/or prevention of cancer including for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

    专利号:US-2025250280-A1
    优先权日:2021-09-03
    标 题 :Nitrogen-containing derivatives of narasin, synthesis and uses thereof
    发明人:RODRIGUEZ RAPHAËL; CAÑEQUE TATIANA; MÜLLER SEBASTIAN; ANTOSZCZAK MICHAL
    权利人:CENTRE NAT RECH SCIENT; INST NAT SANTE RECH MED; INST CURIE
    摘要:The present invention relates to nitrogen-containing derivatives of narasin having the formula (I), as well as synthesis and uses thereof, in particular for the treatment and/or prevention of cancer. Also disclosed are medicaments including the nitrogen-containing derivatives of narasin, which include medicaments for preventing cancer metastasis and/or for preventing cancer recurrence and/or for decreasing resistance to a chemotherapy in a subject.

    专利号:US-2024360247-A1
    优先权日:2021-08-10
    标 题:Compositions and methods for treatment of cancer
    发明人:CHATTERJEE SUBROTO
    权利人:UNIV JOHNS HOPKINS
    摘要:Compositions in the prevention and treatment of cancers, such as colorectal cancer or diseases associated with abnormal levels of β-1,4-galactosyltransferase-V (β-1,4-GalT-V), include at least one inhibitor of glycosphingolipid synthesis.

    专利号:US-11781178-B2
    优先权日:2017-12-15
    标题:Methods and compositions for the amplification of mRNA
    发明人:DECKER WILLIAM K; KONDURI VANAJA
    权利人:BAYLOR COLLEGE MEDICINE
    摘要:Provided herein are compositions and methods for the synthesis, amplification, and in vitro transcription of full-length cDNA, or cDNA fragments. Methods are provided for reverse transcription of RNA and amplification for in vitro transcription. Further provided are method for loading of dendritic cells with the RNA and homologous lysate for immune stimulation.

    专利号:WO-2024117980-A1
    优先权日:2022-12-02
    标题 :Compounds for modulating src family kinases and uses thereof
    发明人:KUMAR ALAN PREM; SETHI GAUTAM; LEE E HUI CLARISSA; - BASAPPA; RANGAPPA KANCHUGARAKOPPAL S; MOHAN CHAKRABHAVI DHANANJAYA
    权利人:NAT UNIV SINGAPORE; UNIV OF MYSORE
    摘要:The present invention relates to chalcone (CHL) compounds, their synthesis, and applications in modulating the activity of Src Family Kinases (SFKs), specifically Lyn kinase, and methods of use in treating various diseases and conditions associated with aberrant activity of Src Family Kinases.

    专利号:US-9295731-B2
    优先权日:2013-04-01
    标题 :Cleavable drug conjugates, compositions thereof and methods of use
    发明人:NGUYEN MARK QUANG
    权利人:NGUYEN MARK QUANG
    摘要:Base-labile crosslinkers, base-labile conjugates comprising such crosslinkers, methods of their synthesis and use are disclosed.
    台州市科瑞生物技术有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.pharm-intermediates.com
    企业联系电话:0576-88813233👤
    📞台州市科瑞生物技术有限公司 ⚠️参考联系方式
    联系人:金崇光
    电话:0576-88813233
    手机:13396860566
    传真:0576-88813233
    邮箱:sales@pharm-intermediates.com
    通信地址: 台州市开发大道东段288号
    邮编: 318000
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:台州市开发大道东段288号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    戊言医药科技(上海)有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.wuyanpharm.com
    企业联系电话:021-61001086👤
    📞戊言医药科技(上海)有限公司 ⚠️参考联系方式
    联系人:邱先生
    电话:021-61001086
    手机:13671938079

    邮箱:1364178184@qq.com
    通信地址: 上海市浦东新区沪南公路8666弄19栋5楼
    邮编: 200135
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:上海市浦东新区沪南公路8666弄19栋5楼
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    济南中道安然化工有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.zdarchem.com
    企业联系电话:18678233466👤
    📞济南中道安然化工有限公司 ⚠️参考联系方式
    联系人:刘军
    电话:18678233466


    邮箱:sales@zdarchem.com
    通信地址: 济南市高新区康虹路正丰路环保科技园
    邮编: 250014
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:济南市高新区康虹路正丰路环保科技园
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Vidal SI, Menta N, Friedman A. To Acne and Beyond: A Review of Sarecycline's Off-Label Uses. J Drugs Dermatol. 2024 Sep 1;23(9):792-793. 39(9):e4889. doi: 10.1002/bio.4889. 17(6):50-54.
    5: Baldwin HE, Graber E, Harper JC, Alexis AF, Stein Gold L, Kircik L, Del Rosso J, Hebert AA, Rieder EA, Fried RG, Narayanan S, Koscielny V, Kasujee I. INDIVIDUAL ARTICLE: Sarecycline Improves Acne Severity, Symptoms, and Psychosocial Burden in Non-nodular Acne Vulgaris: PROSES Study. J Drugs Dermatol. 2024 Feb 1;23(2):SF405634s12-SF405634s18. doi: 10.36849/JDD.SF405634. 23(2):SF405634s5-SF405634s11. doi: 10.36849/JDD.SF405634. 23(2):e55-e56. doi: 10.36849/JDD.7638. 90(5):1006.e1-1006.e30. doi: 10.1016/j.jaad.2023.12.017. Epub 2024 Jan 30. 66(1695):17-20. doi: 10.58347/tml.2024.1695a. 77(4):230-234. doi: 10.2533/chimia.2023.230. 79(1):96-99. doi: 10.1093/jac/dkad352.
    12: Poplausky D, Young JN, Dubin DP, Tremblay D, Gulati N. Dasatinib-Associated Acneiform Eruption Successfully Treated With Sarecycline in a Patient With Chronic Myeloid Leukemia. Cureus. 2023 Sep 21;15(9):e45697. doi: 10.7759/cureus.45697.

    合成参考文献


    参考文献:10.3816/clc.2006.n.020
    摘要:Lee D, Gautschi O. Clinical development of SRC tyrosine kinase inhibitors in lung cancer. Clin Lung Cancer. 2006 May;7(6):381–4. doi: 10.3816/clc.2006.n.020.
    参考文献:10.1007/s10549-008-9997-1
    摘要:Jones RJ, Young O, Renshaw L, Jacobs V, Fennell M, Marshall A, Green TP, Elvin P, Womack C, Clack G, Dixon JM. Src inhibitors in early breast cancer: a methodology, feasibility and variability study. Breast Cancer Research and Treatment. 2008 Apr 14;114(2):211–21. doi: 10.1007/s10549-008-9997-1.
    参考文献:10.4161/cbt.12.3.16218
    摘要:Mitchell C, Hamed HA, Cruickshanks N, Tang Y, Bareford MD, Hubbard N, Tye G, Yacoub A, Dai Y, Grant S, Dent P. Simultaneous exposure of transformed cells to SRC family inhibitors and CHK1 inhibitors causes cell death. Cancer Biol Ther. 2011 Aug 01;12(3):215–28.
    参考文献:10.1186/bcr3650
    摘要:Formisano L, Nappi L, Rosa R, Marciano R, D’Amato C, D’Amato V, Damiano V, Raimondo L, Iommelli F, Scorziello A, Troncone G, Veneziani BM, Parsons SJ, De Placido S, Bianco R. RETRACTED ARTICLE: Epidermal growth factor-receptor activation modulates Src-dependent resistance to lapatinib in breast cancer models. Breast Cancer Res. 2014 May 05;16(3). doi: 10.1186/bcr3650.
    参考文献:10.1002/pros.23119
    摘要:Posadas EM, Ahmed RS, Karrison T, Szmulewitz RZ, O'Donnell PH, Wade JL, Shen J, Gururajan M, Sievert M, Stadler WM. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate. 2016 Feb 15;76(3):286–93.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知